TriGemX Bio develops novel medicines for people with migraine, led by elismetrep, an oral TRPM8 channel blocker intended as a first-in-class acute treatment.

Founders

• Charles Zuker · co-founder
  He is a member of the National Academy of Sciences, a Fellow of the American Academy of Arts and Sciences, a Howard Hughes Medical Institute Investigator, a professor at Columbia University, and an investigator at Columbia's Mortimer B. Zuckerman Mind Brain Behavior Institute.
• Tom Maniatis · co-founder
  He is a member of the National Academy of Sciences, a Fellow of the American Academy of Arts and Sciences, a Lasker Award recipient, a professor at Columbia University, and an investigator at Columbia's Mortimer B. Zuckerman Mind Brain Behavior Institute.
• Richard Axel · co-founder
  He is a member of the National Academy of Sciences, a Fellow of the American Academy of Arts and Sciences, a Nobel laureate, a Howard Hughes Medical Institute Investigator, a professor at Columbia University, and co-director of Columbia's Zuckerman Institute.